

Design and Pharmacological Evaluation of Metal-Based Coordination Complexes for Enhanced Anticancer and Antimicrobial Activity

Snehal Laxman Durande¹ and Dr. Sunil S Menghani²

¹Research Scholar, ²Professor

Department of Pharmaceutical Chemistry

Sunrise University, Alwar (Rajasthan)

Abstract: Metal-based coordination complexes have emerged as promising therapeutic candidates because coordination with biologically active ligands can substantially modify their physicochemical, pharmacological, and biological properties. The present research paper focuses on the design and pharmacological evaluation of metal-based coordination complexes with enhanced anticancer and antimicrobial activities. The proposed approach involves the selection of suitable transition-metal ions and biologically relevant ligands followed by controlled complexation, purification, and structural characterization. The synthesized complexes can be evaluated using spectroscopic and analytical techniques to establish their coordination behavior, stability, and molecular structure.

Pharmacological assessment includes in vitro anticancer screening against selected cancer cell lines and antimicrobial evaluation against representative Gram-positive bacteria, Gram-negative bacteria, and fungal strains. Parameters such as percentage growth inhibition, IC_{50} values, minimum inhibitory concentration, and selectivity toward malignant cells may be used to compare the biological performance of the complexes with their corresponding free ligands and suitable reference drugs. Metal coordination may enhance biological activity through mechanisms involving DNA interaction, oxidative stress, enzyme inhibition, membrane disruption, mitochondrial dysfunction, and interference with essential cellular pathways.

Keywords: Metal-based coordination complexes, Antimicrobial activity, pharmacological evaluation, coordination chemistry, cancer cell lines, antibacterial activity, antifungal activity.

I. INTRODUCTION

The increasing prevalence of cancer and antimicrobial resistance has created a strong demand for new therapeutic agents with novel mechanisms of action. Conventional organic drugs frequently face limitations such as resistance, inadequate selectivity, poor bioavailability, and dose-related toxicity. Metal-based compounds offer an alternative pharmacological platform because metal ions possess distinctive coordination, redox, catalytic, and structural properties that can be exploited in drug design. Coordination of metal ions with organic ligands can alter molecular charge, geometry, lipophilicity, stability, cellular uptake, and interaction with biological macromolecules. These modifications may produce biological properties that differ considerably from those of the individual metal ions or free ligands.

The success of platinum-based anticancer agents established the importance of metal coordination chemistry in modern medicinal chemistry. However, concerns related to toxicity, resistance, and adverse effects have encouraged researchers to investigate alternative metals and ligand systems. Transition metals such as copper, cobalt, nickel, zinc, manganese, iron, and ruthenium have attracted considerable interest because they can participate in different coordination geometries and biological processes. Their complexes may interact with DNA, proteins, enzymes, membranes, and intracellular redox systems. Similarly, metal complexes containing nitrogen-, oxygen-, sulfur-, or mixed-donor ligands may exhibit broad-spectrum antimicrobial activity.



The rational design of coordination complexes requires simultaneous consideration of metal identity, ligand structure, donor atoms, coordination number, geometry, oxidation state, and stability. Pharmacological evaluation is equally important because enhanced chemical stability does not necessarily correspond to enhanced biological efficacy. Therefore, biological screening should compare newly designed complexes with free ligands and appropriate reference compounds. Anticancer investigations may include cytotoxicity assays, morphological assessment, apoptosis-related studies, and mechanistic investigations, whereas antimicrobial evaluation may involve minimum inhibitory concentration and minimum bactericidal or fungicidal concentration measurements.

The present study therefore emphasizes an integrated strategy combining coordination chemistry, physicochemical characterization, and pharmacological screening. The ultimate objective is to identify metal–ligand combinations capable of producing improved anticancer and antimicrobial responses and to establish relationships between molecular structure and biological performance.

II. DESIGN AND SYNTHESIS OF METAL-BASED COORDINATION COMPLEXES

The design of metal-based coordination complexes should begin with the selection of metal ions and ligands according to their expected biological and coordination properties. Transition-metal ions are particularly suitable because they can adopt multiple oxidation states and coordination geometries. Ligands containing donor atoms such as nitrogen, oxygen, sulfur, or phosphorus can be selected to provide stable coordination environments while retaining pharmacologically relevant functional groups. Schiff bases, hydrazones, thiosemicarbazones, heterocyclic compounds, phenolic ligands, and other bioactive molecules represent useful ligand classes for coordination-based drug design.

Complex formation may be achieved through conventional solution-phase reactions in which the ligand is combined with an appropriate metal salt under controlled stoichiometric, temperature, pH, and reaction-time conditions. The reaction mixture may be subjected to stirring or reflux followed by cooling, filtration, washing, and drying of the resulting complex. Different metal-to-ligand ratios can be investigated to identify stable complexes with reproducible compositions.

The design process should consider whether metal coordination improves relevant pharmacological properties. Complex formation can modify lipophilicity and molecular size, potentially influencing cellular penetration. It may also facilitate redox reactions or provide a mechanism for generating reactive oxygen species under biological conditions. At the same time, excessive reactivity may increase nonspecific toxicity, making stability and selectivity important considerations.

A comparative experimental design can be used to evaluate the contribution of coordination to biological activity.

Component	Proposed consideration	Purpose
Metal ion	Cu, Zn, Co, Ni, Mn, Fe or Ru	Provide different coordination and biological properties
Ligand	Bioactive N/O/S donor ligand	Provide pharmacophore and coordination sites
Metal ratio	1:1, 1:2 or optimized ratio	Establish stable complex composition
Reaction medium	Suitable aqueous/organic solvent	Facilitate complex formation
Reaction conditions	Controlled pH and temperature	Improve reproducibility
Product processing	Filtration, washing and drying	Obtain purified complexes
Reference materials	Free ligand and standard drug	Determine the effect of metal coordination

III. PHYSICOCHEMICAL AND STRUCTURAL CHARACTERIZATION

Comprehensive characterization is essential for confirming the formation and proposed structure of newly synthesized metal complexes. The physical appearance, color, melting or decomposition behavior, solubility, and stability can provide preliminary information regarding complex formation. Elemental analysis may be employed to determine the percentage composition of carbon, hydrogen, nitrogen, sulfur, and the relevant metal, thereby helping to establish the empirical formula.



Infrared spectroscopy can provide important information about ligand functional groups and their involvement in coordination. Changes in characteristic stretching frequencies after complex formation can indicate whether donor atoms participate in binding to the metal center. Ultraviolet-visible spectroscopy may provide information regarding ligand-centered transitions, charge-transfer transitions, and, where applicable, d–d transitions. Nuclear magnetic resonance spectroscopy can be useful for diamagnetic complexes, while mass spectrometry may assist in determining molecular mass and fragmentation patterns.

Additional techniques such as magnetic susceptibility measurements, conductivity studies, powder X-ray diffraction, thermogravimetric analysis, and single-crystal X-ray diffraction may be employed depending on the availability of instrumentation and the structural complexity of the complexes. These techniques collectively help establish coordination geometry, thermal stability, crystallinity, and molecular composition.

Characterization technique	Major information obtained
Elemental analysis	Empirical composition of complexes
FTIR spectroscopy	Functional groups and coordination sites
UV-visible spectroscopy	Electronic transitions and coordination effects
NMR spectroscopy	Structural environment of ligand nuclei
Mass spectrometry	Molecular mass and fragmentation
Molar conductivity	Ionic or non-ionic character
Magnetic susceptibility	Magnetic behavior and possible geometry
X-ray diffraction	Crystal structure and coordination geometry
TGA/DSC	Thermal stability and decomposition behavior

IV. PHARMACOLOGICAL EVALUATION FOR ANTICANCER ACTIVITY

The anticancer potential of metal-based coordination complexes can be investigated through in vitro cytotoxicity assays using appropriate cancer cell lines. A suitable non-malignant cell line should also be included to provide preliminary information regarding selectivity. Cells can be exposed to different concentrations of the synthesized complexes for a defined incubation period, followed by measurement of cellular viability using an established assay such as MTT, resazurin, or another validated metabolic assay.

The concentration required to inhibit 50% of cellular viability, commonly expressed as IC_{50} , can be calculated from concentration–response curves. Lower IC_{50} values indicate greater cytotoxic potency under the experimental conditions. However, cytotoxicity alone cannot establish the precise mechanism of action. Additional investigations may therefore assess apoptosis, reactive oxygen species generation, mitochondrial membrane potential, cell-cycle distribution, DNA damage, and expression of selected molecular markers.

Metal complexes may exert anticancer effects through several complementary mechanisms. Some compounds can interact directly or indirectly with DNA, while others may inhibit enzymes, disturb mitochondrial function, generate oxidative stress, or interfere with cellular signaling. The ligand can also influence the biological behavior of the metal center by changing cellular uptake and intracellular distribution.

Evaluation parameter	Experimental purpose	Expected interpretation
Cell viability	Determine overall cytotoxic response	Reduced viability indicates anticancer potential
IC_{50}	Quantify potency	Lower IC_{50} indicates greater potency
Selectivity index	Compare cancer and normal-cell responses	Higher value suggests better selectivity
ROS generation	Assess oxidative mechanism	Increased ROS may contribute to cytotoxicity



Apoptosis assay	Identify programmed cell death	Increased apoptosis supports apoptotic mechanism
Cell-cycle analysis	Determine cell-cycle effects	Accumulation at specific phases indicates cell-cycle interference
DNA-damage assessment	Examine genotoxic mechanisms	Increased damage supports DNA-directed activity
Mitochondrial assay	Evaluate mitochondrial involvement	Alteration suggests mitochondrial-mediated cytotoxicity

V. ANTIMICROBIAL EVALUATION

The antimicrobial activity of the synthesized coordination complexes can be assessed against representative bacterial and fungal microorganisms. The selection of test organisms should include both Gram-positive and Gram-negative bacteria because differences in cell-wall architecture can influence susceptibility to metal complexes. Appropriate fungal strains may also be included to determine antifungal potential.

Initial screening can be performed using agar diffusion methods, whereas quantitative assessment is preferably obtained through broth dilution procedures for determination of the minimum inhibitory concentration (MIC). The MIC represents the lowest concentration that prevents visible microbial growth under defined experimental conditions. Minimum bactericidal concentration (MBC) or minimum fungicidal concentration (MFC) may subsequently be determined by subculturing from growth-inhibition wells.

The antimicrobial mechanism may involve disruption of microbial membranes, interaction with cellular proteins, inhibition of essential enzymes, interference with nucleic acids, and oxidative damage. Chelation may enhance the lipophilic character of a ligand and facilitate penetration through microbial membranes. Nevertheless, antimicrobial activity should be interpreted alongside complex stability and toxicity data to determine whether the observed activity is therapeutically meaningful.

Microorganism group	Example test organisms	Main parameter
Gram-positive bacteria	<i>Staphylococcus aureus</i> , <i>Bacillus</i> spp.	MIC/MBC
Gram-negative bacteria	<i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i>	MIC/MBC
Fungi	<i>Candida</i> spp., <i>Aspergillus</i> spp.	MIC/MFC
Control	Standard antimicrobial agent	Comparative efficacy
Experimental control	Free ligand/vehicle	Determine contribution of coordination

VI. RESULTS, DISCUSSION AND PHARMACOLOGICAL SIGNIFICANCE

The pharmacological significance of the synthesized complexes should be established by comparing their structural characteristics with anticancer and antimicrobial outcomes. A complex showing substantially greater biological activity than its corresponding free ligand may indicate that metal coordination has improved the pharmacological properties of the ligand. However, enhanced activity should be evaluated together with toxicity toward non-malignant cells and microbial selectivity to avoid interpreting nonspecific toxicity as therapeutic effectiveness.

A structure–activity relationship can be developed by examining the influence of metal identity, oxidation state, ligand donor atoms, coordination geometry, molecular charge, and lipophilicity. Complexes capable of favorable cellular uptake may demonstrate stronger anticancer effects, whereas compounds with appropriate membrane interactions may exhibit enhanced antimicrobial activity. Differences between Gram-positive and Gram-negative organisms may also provide information about the importance of membrane permeability and cellular targets.

The overall comparison should incorporate both chemical and biological data.

Evaluation aspect	Free ligand	Metal complex	Pharmacological significance
Structural stability	Baseline	Expected to change after coordination	Indicates complex integrity



Cancer-cell inhibition	Comparative baseline	May increase after complexation	Indicates anticancer enhancement
Normal-cell toxicity	Reference response	Should ideally remain lower	Indicates selectivity
Antibacterial activity	Baseline activity	May be enhanced	Indicates antibacterial potential
Antifungal activity	Baseline activity	May be enhanced	Indicates antifungal potential
MIC	Reference value	Lower value may indicate improvement	Quantifies antimicrobial potency
IC ₅₀	Reference value	Lower value may indicate improvement	Quantifies anticancer potency
Mechanistic response	Ligand-dependent	May involve metal-mediated pathways	Supports structure–activity interpretation

Rationally designed metal-based coordination complexes represent a versatile platform for developing compounds with dual anticancer and antimicrobial potential. Their biological activity is determined by the combined contribution of the metal center and ligand framework rather than by either component alone. Successful candidates should therefore demonstrate strong biological activity, reproducible chemical characteristics, and an acceptable preliminary selectivity profile. Integrated characterization and pharmacological evaluation can help identify promising lead structures for subsequent mechanistic, pharmacokinetic, toxicity, and in vivo investigations. The approach may ultimately contribute to the development of multifunctional metal-based therapeutic agents capable of addressing important challenges associated with cancer treatment and antimicrobial resistance.

REFERENCES

1. Alessio, E. (2017). Thirty years of the drug candidate KP1019 (FFC14A) and related ruthenium anticancer compounds: A chemical perspective. *European Journal of Inorganic Chemistry*, 2017(13), 1549–1560.
2. Bergamo, A., & Sava, G. (2015). Ruthenium anticancer compounds: Myths and realities of the emerging metal-based drugs. *Dalton Transactions*, 44(41), 17429–17444.
3. Bruijninx, P. C. A., & Sadler, P. J. (2008). New trends for metal complexes with anticancer activity. *Current Opinion in Chemical Biology*, 12(2), 197–206.
4. Dilworth, J. R., & Huetting, R. (2012). Metal complexes for therapy and diagnosis. *Inorganica Chimica Acta*, 389, 3–15.
5. Gasser, G., & Metzler-Nolte, N. (2012). The potential of organometallic complexes in medicinal chemistry. *Current Opinion in Chemical Biology*, 16(1–2), 84–91.
6. Hartinger, C. G., & Dyson, P. J. (2009). Bioorganometallic chemistry—from teaching paradigms to medicinal applications. *Chemical Society Reviews*, 38(2), 391–401.
7. Ndagi, U., Mhlongo, N., & Soliman, M. E. (2017). Metal complexes in cancer therapy—An update from drug design perspective. *Drug Design, Development and Therapy*, 11, 599–616.
8. Ott, I. (2009). Medicinal inorganic chemistry and metal-based drugs. *Journal of Inorganic Biochemistry*, 103(2), 199–200.
9. Santini, C., Pellei, M., Gandin, V., Porchia, M., & Marzano, C. (2014). Advances in copper complexes as anticancer agents. *Chemical Reviews*, 114(1), 815–862.
10. Tisato, F., Marzano, C., Porchia, M., & Pellei, M. (2010). Metal complexes of phosphines and related ligands as anticancer agents. *Anti-Cancer Agents in Medicinal Chemistry*, 10(3), 245–265.
11. Tripathi, R. P., & Saxena, N. (2018). Metal complexes as potential anticancer agents: Recent developments. *Current Medicinal Chemistry*, 25(32), 3784–3810.



12. van Rijt, S. H., & Sadler, P. J. (2009). Current applications and future potential for bioorganometallic chemistry in cancer therapy. *Drug Discovery Today*, 14(23–24), 1089–1097.
13. Weder, J. E., Dillon, C. T., Hambley, T. W., Kennedy, B. J., Lay, P. A., & others. (2002). Copper complexes of non-steroidal anti-inflammatory drugs: An effective strategy for anticancer drug development. *Coordination Chemistry Reviews*, 232(1–2), 195–205.
14. Frei, A., Zuegg, J., Elliott, A. G., Baker, M., Braese, S., Brown, C., Chen, F., Dowson, C. G., Du, W., Jung, N., King, A. P. C., Mühlenfeld, A., & others. (2020). Metal complexes as a promising source for new antibiotics. *Chemical Science*, 11(10), 2627–2639.
15. Lemire, J. A., Harrison, J. J., & Turner, R. J. (2013). Antimicrobial activity of metals: Mechanisms, molecular targets and applications. *Nature Reviews Microbiology*, 11(6), 371–384.
16. Lemire, J. A., Kalan, L., Brackman, G., De Vos, D., & Turner, R. J. (2017). The potential of metal-based antimicrobial agents in the fight against antimicrobial resistance. *Current Opinion in Microbiology*, 39, 1–8.

